Loading clinical trials...

A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone in Children With Achondroplasia | Clinical Trials | Clareo Health

UNKNOWNPHASE4

A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone in Children With Achondroplasia

A Multicenter, Open-label, Single Arm Phase IV Clinical Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone in Children With Achondroplasia

NCT05353192•Changchun GeneScience Pharmaceutical Co., Ltd.

View on ClinicalTrials.gov

Summary

To Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone in Children with Achondroplasia

Eligibility

Age

2 - 10 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•2-10 years old;
•In Tanner I stage;
•ACH, documented and confirmed by genetic testing;
•Short stature;
•Ambulatory and able to stand or walk without assistance;
•Parent(s) or guardian(s) consent；
•Had never been treated with growth hormone

Exclusion Criteria

•Short stature condition other than ACH;
•Evidence of growth plate closure (proximal tibia, distal femur);
•Had a fracture of the long bones within 6 months prior to screening;
•Planned or expected bone-related surgery;
•Chronic diseases condition that affect bone metabolism and weight;
•Severe intracranial hypertension

Locations (1)

Children's Hospital of Fudan University

Shanghai, Shanghai Municipality, China

Key Dates

Start Date

September 23, 2022

Primary Completion Date

February 1, 2025

Completion Date

February 1, 2025

Last Updated

February 28, 2023

Enrollment

ESTIMATED participants

Conditions

Achondroplasia

Interventions

Recombinant human growth hormone

DRUG

Contacts

Yanru Wu

CONTACT

+86 15843110489 wuyanru@gensci-china.com

A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia

NCT06079398

Achondroplasia

View study

ENROLLING_BY_INVITATIONPHASE2/PHASE3

A Clinical Trial to Investigate Long-term Safety, Tolerability, and Efficacy of Weekly Subcutaneous Doses With TransCon CNP in Children and Adolescents With Achondroplasia

NCT05929807

Achondroplasia

View study

ACTIVE_NOT_RECRUITINGPHASE2

An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 28, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone in Children With Achondroplasia

Inclusion Criteria

Exclusion Criteria

A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia

A Clinical Trial to Investigate Long-term Safety, Tolerability, and Efficacy of Weekly Subcutaneous Doses With TransCon CNP in Children and Adolescents With Achondroplasia

An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia

A Study Of Safety, Tolerability And Effectiveness Of Recifercept In Children With Achondroplasia

Lifetime Impact Study for Achondroplasia

Radiological Analysis on Patients With Achondroplasia Disorder